These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33065793)

  • 1. Meta-analysis of excision repair cross complementary gene 1 (ERCC1) expression and platinum chemosensitivity in patients with ovarian cancer.
    Wu J; Li R; Chen X; Chen C; Chen H; Ma B
    Ann Palliat Med; 2020 Sep; 9(5):3428-3435. PubMed ID: 33065793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis.
    Zhang C; Gao S; Hou J
    Int J Biol Markers; 2020 Dec; 35(4):12-19. PubMed ID: 33126828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
    Zhang Y; Cao S; Zhuang C; Chen J; Chen X; Sun H; Lin S; Lin B
    J Ovarian Res; 2021 Jun; 14(1):80. PubMed ID: 34148553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
    Li FY; Ren XB; Xie XY; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    Wu X; Lu W; Jiang C; Zhang D; Zhang W; Cui Y; Zhuo Z; Mei H; Wang Y; Zhang M; Chen S
    PLoS One; 2023; 18(5):e0284825. PubMed ID: 37141338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
    Tang N; Lyu D; Zhang Y; Liu H
    BMC Womens Health; 2017 Jun; 17(1):43. PubMed ID: 28623887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer.
    Li G; Cheng D
    Evid Based Complement Alternat Med; 2020; 2020():7376568. PubMed ID: 32419821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
    Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
    Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
    Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
    Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
    Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
    Yang Y; Luo X; Yang N; Feng R; Xian L
    PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
    Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.